JDJohn Dunlop

John Dunlop

*This is an algorithmically generated author record based on publicly available information.

John Dunlop has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channels and Pain

    by J. Dunlop, D. Vasilyev, P. Lu, T. Cummons, M. R. Bowlby

    Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels underlie the pacemaker currents in neurons and cardiac cells designated as Ih and If, respectively. HCN channels are activated at negative membrane potentials and specifically upon repolarization following action potential firing resulting in a depolarizing current influencing the threshold for subsequent action potential generation. Consequently, HCN channels and Ih/If play a critical role in regulating excitability and rhythmic activity in excitable cells. The distribution of the four HCN channel subtypes has been studied in some detail in sensory neurons demonstrating a diverse and widespread distribution and raising the question as to their potential involvement in pain pathophysiology, frequently ascribed to aberrant neuronal hyperexcitability. This review discusses the evidence implicating a role for HCN channels in pain.


  • Old and New Pharmacology: Positive Allosteric Modulation of the α7 Nicotinic Acetylcholine Receptor by the 5-Hydroxytryptamine2B/C Receptor Antagonist SB-206553 (3,5-Dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b′]di pyrrole-1(2 H)-carboxamide)

    by John Dunlop, Tim Lock, Brian Jow, Fabrizio Sitzia, Steven Grauer, Flora Jow, Angela Kramer, Mark R. Bowlby, Andrew Randall, Dianne Kowal, et al.

    The α7 nicotinic acetylcholine receptor (nAChR) has been implicated in Alzheimer9s disease and schizophrenia, leading to efforts targeted toward discovering agonists and positive allosteric modulators (PAMs) of this receptor. In a Ca2+ flux fluorometric imaging plate reader assay, SB-206553 (3,5-dihydro-5-methyl -N-3-pyridinylbenzo [1, 2-b:4,5 -b′]-di pyrrole-1(2H)-carboxamide), a compound known as a 5-hydroxytryptamine2B/2C receptor antagonist, produced an 8-fold potentiation of the evoked calcium signal in the presence of an EC20 concentration of nicotine and a corresponding EC50 of 1.5 μM for potentiation of EC20 nicotine responses in GH4C1 cells expressing the α7 receptor. SB-206553 was devoid of direct α7 receptor agonist activity and selective against other nicotinic receptors. Confirmation of the PAM activity of SB-206553 on the α7 nAChR was obtained in patch-clamp electrophysiological experiments in GH4C1 cells, where it failed to evoke any detectable currents when applied alone, yet dramatically potentiated the currents evoked by an EC20 (17 μM) and EC100 (124 μM) of acetylcholine (ACh). Native nicotinic receptors in CA1 stratum radiatum interneurons of rat hippocampal slices could also be activated by ACh (200 μM), an effect that was entirely blocked by the α7-selective antagonist methyllycaconitine (MLA). These ACh currents were potentiated by SB-206553, which increased the area of the current response significantly, resulting in a 40-fold enhancement at 100 μM. In behavioral experiments in rats, SB-206553 reversed an MK-801 (dizocilpine maleate)-induced deficit in the prepulse inhibition of acoustic startle response, an effect attenuated in the presence of MLA. This latter observation provides further evidence in support of the potential therapeutic utility of α7 nAChR PAMs in schizophrenia.


  • Acid sensing ion channel (ASIC) inhibitors exhibit anxiolytic-like activity in preclinical pharmacological models

    by Jason M. Dwyer, Stacey J. Sukoff Rizzo, Sarah J. Neal, Qian Lin, Flora Jow, Robert L. Arias, Sharon Rosenzweig-Lipson, John Dunlop, Chad E. Beyer

    Rationale Acid sensing ion channels (ASICs) are proton-gated ion channels located in the central and peripheral nervous systems. Of particular interest is ASIC1a, which is located in areas associated with fear and anxiety behaviors. Recent reports suggest a role for ASIC1a in preclinical models of fear conditioning and anxiety. Objectives The present experiments evaluated various ASIC inhibitors in preclinical models of autonomic and behavioral parameters of anxiety. In addition, neurochemical studies evaluated the effects of an ASIC inhibitor (A-317567) on neurotransmitter levels in the amygdala. Results In electrophysiological studies using hippocampal primary neuronal cultures, three ASIC inhibitors (PcTX-1, A-317567, and amiloride) produced concentration-dependent inhibition of acid-evoked currents. In the stress-induced hyperthermia model, acute administration of psalmotoxin 1 (PcTX-1; 10–56 ng, i.c.v.), A-317567 (0.1–1.0 mg/kg, i.p.), and amiloride (10–100 mg/kg, i.p.) prevented stress-induced elevations in core body temperature. In the four-plate test, acute treatment with PcTX-1 (10–56 ng, i.c.v.) and A-317567 (0.01–0.1 mg/kg, i.p.), but not amiloride (3–100 mg/kg, i.p.), produced dose-dependent and significant increases in the number of punished crossings relative to vehicle-treated animals. Additionally, PcTX-1 (56–178 ng, i.c.v.), A-317567 (0.1–10 mg/kg, i.p.), and amiloride (10–100 mg/kg, i.p.) lacked significant anxiolytic-like activity in the elevated zero maze. In neurochemical studies, an infusion of A-317567 (100 µM) into the amygdala significantly elevated the extracellular levels of GABA, but not glutamate, in this brain region. Conclusions These findings demonstrate that ASIC inhibition produces anxiolytic-like effects in some behavioral models and indicate a potential role for GABAergic mechanisms to underlie these anxiolytic-like effects.


  • Ion Channel Screening

    by John Dunlop, Mark Bowlby, Ravikumar Peri, Gregory Tawa, James LaRocque, Veronica Soloveva, John Morin

    Ion channels are attractive targets for drug discovery with recent estimates indicating that voltage and ligandgated channels account for the third and fourth largest gene families represented in company portfolios after the G protein coupled and nuclear hormone receptor families. A historical limitation on ion channel targeted drug discovery in the form of the extremely low throughput nature of the gold standard assay for assessing functional activity, patch clamp electrophysiology in mammalian cells, has been overcome by the implementation of multi-well plate format cell-based screening strategies for ion channels. These have taken advantage of various approaches to monitor ion flux or membrane potential using radioactive, non-radioactive, spectroscopic and fluorescence measurements and have significantly impacted both high-throughput screening and lead optimization efforts. In addition, major advances have been made in the development of automated electrophysiological platforms to increase capacity for cell-based screening using formats aimed at recapitulating the gold standard assay. This review addresses the options available for cell-based screening of ion channels with examples of their utility and presents case studies on the successful implementation of high-throughput screening campaigns for a ligand-gated ion channel using a fluorescent calcium indicator, and a voltage-gated ion channel using a fluorescent membrane potential sensitive dye.


  • Functional screening of α7 nicotinic receptor ligands

    by John Dunlop, Ravikumar Peri, Georg C Terstappen, Mark Bowlby

    The α7 nicotinic acetylcholine receptor, a ligand-gated ion channel, is an attractive drug discovery target in schizophrenia and Alzheimer's disease. We have evaluated the various approaches to discovering ligands targeting the α7 nicotinic receptor to define the current paradigm driving drug discovery efforts in this area. Assays using functional read-outs as a consequence of α7 nicotinic receptor activation have been reviewed. Functional assays using fluorescence-based optical methods in combination with direct electrophysiological recordings of channel function currently provide an integrated approach to the discovery of α7 nicotinic receptor targeted ligands.


  • Top Cited Papers

    High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology

    by John Dunlop, Mark Bowlby, Ravikumar Peri, Dmytro Vasilyev, Robert Arias

    Ion channels represent highly attractive targets for drug discovery and are implicated in a diverse range of disorders, in particular in the central nervous and cardiovascular systems. Moreover, assessment of cardiac ion-channel activity of new chemical entities is now an integral component of drug discovery programmes to assess potential for cardiovascular side effects. Despite their attractiveness as drug discovery targets ion channels remain an under-exploited target class, which is in large part due to the labour-intensive and low-throughput nature of patch-clamp electrophysiology. This Review provides an update on the current state-of-the-art for the various automated electrophysiology platforms that are now available and critically evaluates their impact in terms of ion-channel screening, lead optimization and the assessment of cardiac ion-channel safety liability.


  • In vitro screening strategies for nicotinic receptor ligands

    by John Dunlop, Renza Roncarati, Brian Jow, Hendrick Bothmann, Tim Lock, Dianne Kowal, Mark Bowlby, Georg C. Terstappen